SENIOR Management

CEO, President and Director  

John Lai  

Mr. Lai has been a director and senior executive officer since March 2014, serving in various capacities that include Principal Financial Officer, President and CEO; and serving as our Chief Executive Officer from March 2014 to May 2017 and June 2019 to present. From March 2012 to April 2016, Mr. Lai also was Chief Executive Officer and a director of Blue Earth Resources, Inc., a small public company which acquired and managed working interests in producing oil and gas leases in Louisiana. Mr. Lai has over thirty years of senior executive and operational management and financial experience while holding key executive positions with several public companies in various industries.


In 1992 Mr. Lai founded and until December 2012 was the principal owner and President of Genesis Capital Group, Inc., which provided significant consulting services to many public and private companies in the powersports, technology and other industries, while advising its clients in corporate development, mergers and acquisitions, and private and public capital-raising through equity offerings. Mr. Lai’s role as a co-founder of the company and his many years of experience as a chief executive officer of many public or private companies are material factors regarding his qualifications to serve on our Board of Directors.

Chief Financial Officer 

John Carruth 

Mr. Carruth has spent several years in the accounting field with continually-progressing responsibilities. His areas of expertise include internal controls over financial reporting, SEC reporting, and GAAP compliance. He holds three degrees in accounting, including a Master of Accountancy degree from the University of Minnesota (2016) where the coursework surrounded navigating the SEC, SOX and the Dodd Frank Act. He has been employed at Merrill Corporation, where he worked on SEC reporting; at Prime Therapeutics, where he worked to fix major discrepancies within their accounts; and most recently, at Supervalu as a Senior Accountant focusing on GAAP compliance and special projects.

BOARD OF DIRECTORS

CEO, President and Director  

John Lai  

Mr. Lai has been a director and senior executive officer since March 2014, serving in various capacities that include Principal Financial Officer, President and CEO; and serving as our Chief Executive Officer from March 2014 to May 2017 and June 2019 to present. From March 2012 to April 2016, Mr. Lai also was Chief Executive Officer and a director of Blue Earth Resources, Inc., a small public company which acquired and managed working interests in producing oil and gas leases in Louisiana. Mr. Lai has over thirty years of senior executive and operational management and financial experience while holding key executive positions with several public companies in various industries.


In 1992 Mr. Lai founded and until December 2012 was the principal owner and President of Genesis Capital Group, Inc., which provided significant consulting services to many public and private companies in the powersports, technology and other industries, while advising its clients in corporate development, mergers and acquisitions, and private and public capital-raising through equity offerings. Mr. Lai’s role as a co-founder of the company and his many years of experience as a chief executive officer of many public or private companies are material factors regarding his qualifications to serve on our Board of Directors.

Director 

David Deming 

Mr. Deming serves as chief investment officer for the BBIC. Mr. Deming brings a wealth of experience fostering deep relationships with asset allocators across the spectrum including institutions, pensions, endowments, family offices and high net worth investors. His career has included roles as director of marketing and investor relations at BCCM Advisors, head of business development at Asymmetric Capital Management, partner and director of marketing at Arbor Capital Management, president and marketing director at Leuthold, Weeden & Associates, L.P., account executive at Paine Webber and Merrill Lynch, PM, analyst at Windsor Financial, and floor trader at the CBOT. Mr. Deming earned a bachelor of science degree in finance from the University of Wisconsin La Crosse. Mr. Deming is a board member of Ironwood Springs Christian Ranch, the largest wheelchair sports camp in the country, and PetVivo Holdings, Inc., an emerging biomedical device company. He has a passion for servant-mentor leadership, driving core cultural values to collaborate, encourage, equip and uplift so that serving others ultimately benefits the individual and the organization. He and his wife live in Minneapolis and have four adult children.

Director 

David Masters, Ph.D. 

Dr. Masters has been a director since April 2015, and served as our Chief Technical Officer from April 2015 to December 2017. Dr. Masters is the founder of and served as Chief Executive Officer and Chief Technology Officer of Gel-Del Technologies, Inc., from 1999 to December 2017, while for Gel-Del he developed and obtained significant patents for the proprietary biomaterial technology and product applications acquired by us from Gel-Del.  


Dr. Masters is recognized internationally as a leading expert in biomaterials and local drug delivery, and over the past twenty years he has developed and obtained patents for many novel biomaterials and drug delivery products, including implantable medical devices for neurologic, vascular, orthopedic, urologic and dermal applications. Dr. Masters’ former academic career included teaching courses and doing significant research at Harvard Medical School and The Mayo Clinic. He received a B.A. Degree in Biochemistry, a Master’s Degree in Chemistry, and a Ph.D. in Behavioral and Neural Sciences from Rutgers University.

Director & Secretary 

John F. Dolan 

Mr. Dolan has been a director since March 2014, and he served as our Chief Financial Officer from March 2014 to November 2017. Since March 2013, Mr. Dolan also has served as corporate and intellectual property (IP) counsel for KILO, Inc., an alternative energy company. From June 2000 to July 2012, Mr. Dolan was a shareholder in the intellectual property group of the Minneapolis law firm of Fredrikson & Byron, where he specialized in securing and protecting domestic and foreign patent and other IP rights for various clients including biomaterials technology and products.  


During the past five years, Mr. Dolan also has provided consulting services to several early stage companies on all aspects of IP asset protection as well as new technology and corporate development. His extensive career in the intellectual technology field includes serving as a patent examiner with the U.S. Patent and Trademark Office (USPTO).  

Director 

Randall A. Meyer 

Mr. Dolan has been a director since March 2014, and he served as our Chief Financial Officer from March 2014 to November 2017. Since March 2013, Mr. Dolan also has served as corporate and intellectual property (IP) counsel for KILO, Inc., an alternative energy company. From June 2000 to July 2012, Mr. Dolan was a shareholder in the intellectual property group of the Minneapolis law firm of Fredrikson & Byron, where he specialized in securing and protecting domestic and foreign patent and other IP rights for various clients including biomaterials technology and products.  


During the past five years, Mr. Dolan also has provided consulting services to several early stage companies on all aspects of IP asset protection as well as new technology and corporate development. His extensive career in the intellectual technology field includes serving as a patent examiner with the U.S. Patent and Trademark Office (USPTO).  

Director 

Robert J. Rudelius 

Mr. Rudelius is the CEO and Managing Director of Noble Ventures, LLC, a company he founded in 2001 that provides advisory and consulting services to early and mid-stage companies in the information technology, communications, medical technology and social e-commerce industries. From April 1999 through May 2001, when it was acquired by StarNet L.P., Mr. Rudelius was the founder, Chairman and CEO of Media DVX, Inc., a start-up business that provided a satellite-based, IP-multi casting alternative to transmitting television commercials via analog videotapes to television stations, networks and cable television operators throughout North America.


From April 1998 to April 1999, Mr. Rudelius was the President and COO of Control Data Systems, Inc., during which time Mr. Rudelius reorganized and re-positioned the software company as a professional technology services company, resulting in the successful sale of the company to British Telecom. From October 1995 through April 1998, Mr. Rudelius was the founding Managing Partner of AT&T; Solution’s Media, Entertainment &; Communications industry group.  

From January 1990 through September 1995, Mr. Rudelius was a partner in McKinsey &; Company’s Information, Technology and Systems practice, during which time he headed the practice in Japan and the United Kingdom. Mr. Rudelius began his career at Arthur Andersen &; Co. where he was a leader in the firm’s financial accounting systems consulting practice. Mr. Rudelius has served as a member of the Axogen, Inc. (AXGN) Board of Directors since September 2010, where he is chairman of the audit committee and a member of the compensation committee.  

Director 

Joseph Jasper  

Mr. Jasper is a Chartered Financial Analyst (CFA) who since 2005 has been Chief Executive Officer of Vermillion Research, an institutional investment firm, while being responsible for its day-to-day operational management. From 2002 to 2005, Mr. Jasper was Managing Director and Director of Fixed Income and Marketing for Piper Jaffray Company. Prior to 2002, he spent 20 years managing, structuring and selling fixed income and equity securities at several leading investment banking firms, including U.S. Bancorp Libra and UBS PaineWebber.


Mr. Jasper also serves as Vice Chairman of the Board of Directors of MicroNet, Inc. and as a director of Windigo Logistics, both privately-held companies. He has previously served as a director or principal advisor to many operating and venture-stage companies across a broad range of industries. Mr. Jasper received a MBA degree from the University of St. Thomas, where he also has served as its Adjunct Professor of Finance.

Director 

James Martin 

Jim is a retired Certified Public Accountant (CPA) and attorney whose career included his responsibility as Partner in Charge of the Firm’s Tax Practice for its Newport Beach Office. In that role he provided and oversaw the rendition of tax services for numerous clients in varied industries including those for which the Firm provided a Certified Audit. He retains his AICPA membership and holds Accounting and Law Degrees from the University of Washington and, on a Fellowship, received a Master of Laws Degree (LLM) from New York University.  

Director 

Scott Johnson 

Scott is a professional licensed Mechanical Engineer having 30 years experience providing product design and development, production engineering and processes, product quality control and auditing, risk management audit and compliance procedures, and other engineering operations for leading medical device manufacturers. Since 2012 he has been the Chief Executive Officer and principal owner of Stratego, Inc., a life sciences consulting corporation he founded. Leading consulting engineering projects of Stratego have included providing key engineering services for defibrillator products of Philips Healthcare, risk management and quality control audit services for Hospira, quality program and remediation management for programmable implant medical devices of St. Jude Medical, and being the Product Engineering Team Leader for PMA Submissions at Zimmer Biomet –Biologics. Mr. Johnson’s lengthy past employment or consulting with leading industry companies includes being Senior Design Engineer for SciMed for five years, being Engineer Project Manager for linear piston pump projects for the life sciences, petroleum and chemical industries during a six-year period while providing engineering services for PumpWorks, Inc., and being FDA compliance project manager at Boston Scientific for four years. His engineering projects for production of medical devices also includes substantial overseas experience with production facilities and procedures in several foreign countries including Mexico, Costa Rica and Dominican Republic.

Director & Chairman 

Gregory Cash 

Greg has more than 35 years senior management and/or key sales and marketing executive experience in the life sciences industry, including being Chief Executive Officer or Division President of leading cardiovascular medical device companies. Since 2011, he has been the Chief Executive Officer and principal owner of Argent International LLC, Minneapolis, MN, a consulting firm he founded to provide management, marketing and financial consulting services to start-up and established companies in the life sciences industry. Prior to founding Argent, Mr. Cash served for over thirty years in senior executive management or marketing roles with leading medical device companies, including five years with Boston Scientific Corporation and over twelve years with Medtronic, Incorporated. His many industry achievements also feature extensive and high-level overseas experience including being Chief Executive Officer or a senior marketing executive of both start-up and established international medical device companies in European countries including The United Kingdom, France and Italy, as well as serving for several years as the Senior Marketing Manager in Asia for all Medtronic product lines.  

Advisory Board

DVM, MS, Dipl. ACVS, Dipl. ACVSMR 

Tracy Turner 

Tracy Turner began his professional career as a farrier and used those skills to help finance his education. He received his DVM degree from Colorado State University in 1978. He completed an internship at the University of Georgia and a surgical residency, as well as a Master of Science degree at Purdue University in 1981. His Master’s thesis was “Thermography of the Lower Limb of the Horse.” He served on the faculty of the Universities of Illinois, Florida and Minnesota. At Minnesota, he was Head of Large Animal Surgery and attained the rank of full Professor before leaving academics to join Anoka Equine Clinic in 2004. 


Turner's primary research efforts have focused on equine lameness with particular interest in equine podiatry, back issues in horses, rehabilitation and thermography. His podiatry research has evaluated the radiographic and morphologic characteristics of hoof imbalance, as well as the differential diagnosis of palmar foot pain (PFP) and the development of PFP treatment strategies. Turner has researched the use of diagnostic imaging techniques for evaluation of equine back problems (including saddle fit) and developed epidemiological data on overriding spinous processes in horses. He pioneered the use of thermography as a diagnostic aid in lameness evaluation, as well as its use in horse welfare regulation. Turner has extensively published on these topics and been invited to lecture nationally and internationally.  

Turner is a Diplomate of the American College of Veterinary Surgeons, a Diplomate of the American College of Sports Medicine and Rehabilitation, and a Fellow of the American Academy of Thermology. He is an active member of the AVMA, AAEP and the American Horse Council. Turner has served as chairman of the AAEP's Farrier Liaison Committee, served on the AAEP Foundation Advisory Council and the AAEP Educational Programs Committee. Presently, he is on the AAEP Board of Directors. He is a past president of the Minnesota Association of Equine Practitioners and a member of the Minnesota Veterinary Medical Association. He is a member of the board of directors of the Minnesota Horse Council and is currently the Minnesota Horse Council vice-president and chair for the Legislative and Horse Welfare committees. He is currently president of the American Academy of Thermology. He has consulted for United States Equestrian Federation, The USDA Horse Protection and Federation Equestrienne International (FEI). He has participated as an instructor at Equitarian Workshops in Mexico, Nicaragua and Costa Rica. He has participated in the Equitarian projects in Honduras and Costa Rica. He is married to veterinarian Julia Wilson and has two sons.  

DVM

Dr. Michael Sterns 

After graduating from the UC Davis School of Veterinary Medicine in 1984, Dr. Sterns began his career as a mobile Equine Veterinarian in his current practice area. He earned his MBA from the Haas School of Business at UC Berkeley in 1990, and spent the next twenty-three years raising equity, negotiating licensing deals, building startups, and running sales and marketing teams in human therapeutics, medical devices and research tools.  


Dr. Sterns returned to small animal clinical practice in 2012 and has been actively engaged in developing a small animal house call practice on The Peninsula and South Bay. Dr. Sterns is also a part time Associate Veterinarian, practicing general small animal medicine and surgery at Alta View Animal Hospital in Mountain View, California, and a Relief Veterinarian for Banfield. He has a special interest in giant breeds, having owned and raised a Newfoundland, a Leonberger, and a very large Maine Coon Cat. 

While continuing to consult with small companies as a product development and marketing consultant, he travels throughout The Peninsula and Silicon Valley and can often be found at Maverick’s Beach and the local brewery -- where he shamelessly hands out business cards and offers veterinary advice to anyone who will listen.  

In his leisure time, Dr. Sterns trains for triathlons by swimming US Masters, biking with his team (the Alpine Chain Gang) and running (when he absolutely must) to survive the last leg of his races.  

Choose your path

Which path would you like to take?

Select the most fitting category for you below:

WITCHER 3
I AM AN

ANIMAL OWNER

FOR VETS
I AM A

veterinarian

WATCH DOGS 2
I AM AN

INVESTOR

FREQUENTLY ASKED QUESTIONS

What is Kush™?

Kush™ is an IA injection of sterilized, hydrogel micro-particles that are wet, slippery and spongy. Our patented technology allows novel self-assembly of elastin, collagen and heparin to mimic cartilage extracellular matrix in both form and function. The Kush particle components are natural, animal based, and tightly cross-linked together to form a strong matrix material that resists enzymatic degradation, inhibits immune cell recognition, and thus, avoids the need for allergy pretesting.  

How does Kush™ work?

Kush™ uses precisely sized micro-particles for optimal joint spacing and for easy intra-articular injection with 18-23 gauge needles. Kush particles are too large to seep through synovial membranes, allowing long duration of their slippery cushion effects to reinforce the joint's articular cartilage and ameliorate or preclude the cartilage defects that cause pain to limit motion.

How long does Kush™ last?

The demonstrated Kush™ effects are long-lasting. Veterinarians are reporting that the positive, cushioning effects typically last about 12 months, depending mostly on activity levels. The Kush particles gradually resorb into the surrounding synovial tissue.

Has Kush™ been studied?

Five plus years of Kush™ case studies provided positive veterinarian testimonials. No adverse effects have been observed or reported other than some mild, short-term injection site responses.

How can I get Kush™ for my animal?

Kush™ is available to your animal through certain licensed and certified veterinarians. To find a veterinarian in your area who can administer Kush™ to your animal, we are happy to help you locate one. Please call us at (952)-681-7913

Kush™ is available to order for licensed and certified veterinarians. Vets may order here.